Evidence map›Paper›PMID 37367188›Full record

ArticleInfectious disease reports2023

SARS-CoV CH.1.1 Variant: Genomic and Structural Insight.

Liliana Bazzani, Elena Imperia, Fabio Scarpa, Daria Sanna, Marco Casu, Alessandra Borsetti, Stefano Pascarella, Nicola Petrosillo, Eleonora Cella, Marta Giovanetti and 1 more

Abstract read
In one paragraph

Article in Infectious disease reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Integrative Genome-Based Survey of the SARS-CoV-2 Omicron XBB.1.16 Variant.International journal of molecular sciences · 2023
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Liliana BazzaniSciences and Technologies for Sustainable Development and One Health, University Campus Bio-Medico of Rome, 00128 Rome, Italy.ORCID 0009-0009-8305-2327
Elena ImperiaUnit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, 00128 Rome, Italy.
Fabio ScarpaDepartment of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy.ORCID 0000-0002-3501-714X
Daria SannaDepartment of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy.ORCID 0000-0002-3058-4663
Marco CasuDepartment of Veterinary Medicine, University of Sassari, 07100 Sassari, Italy.ORCID 0000-0002-5042-4851
Alessandra BorsettiNational HIV/AIDS Research Center (CNAIDS), National Institute of Health, 00161 Rome, Italy.ORCID 0000-0002-5401-135X
Stefano PascarellaDepartment of Biochemical Sciences "A. Rossi Fanelli", Sapienza University of Rome, 00185 Rome, Italy.ORCID 0000-0002-6822-4022
Nicola PetrosilloInfection Prevention and Control-Infectious Disease Service, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.ORCID 0000-0002-2585-7567
Eleonora CellaBurnett School of Biomedical Sciences, University of Central Florida, Orlando, FL 32816, USA.ORCID 0000-0002-7870-9744
Marta GiovanettiSciences and Technologies for Sustainable Development and One Health, University Campus Bio-Medico of Rome, 00128 Rome, Italy.
Massimo CiccozziUnit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, 00128 Rome, Italy.ORCID 0000-0003-3866-9239

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In early February 2023, the Omicron subvariant XBB.1.5, also known as "Kraken", accounted for more than 44% of new COVID-19 cases worldwide, whereas a relatively new Omicron subvariant named CH.1.1, deemed "Orthrus", accounted for less than 6% of new COVID-19 cases during the subsequent weeks. This emerging variant carries a mutation, L452R, previously observed in the highly pathogenic Delta and the highly transmissible BA.4 and BA.5 variants, necessitating a shift to active surveillance to assure adequate preparedness for likely future epidemic peaks. We provide a preliminary understanding of the global distribution of this emerging SARS-CoV-2 variant by combining genomic data with structural molecular modeling. In addition, we shield light on the number of specific point mutations in this lineage that may have functional significance, thereby increasing the risk of disease severity, vaccine resistance, and increased transmission. This variant shared about 73% of the mutations with Omicron-like strains. Our homology modeling analysis revealed that CH.1.1 may have a weakened interaction with ACE2 and that its electrostatic potential surface appears to be more positive than that of the reference ancestral virus. Finally, our phylogenetic analysis revealed that this likely-emerging variant was already cryptically circulating in European countries prior to its first detection, highlighting the importance of having access to whole genome sequences for detecting and controlling emerging viral strains.

Indexed as

CH.1.1 variantgenomic surveillancemutational pattern profileSARS-CoV-2

Identifiers

PMID37367188
PMCPMC10298543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.